However, even CAR-T cell therapies face many obstacles, including off-tumor toxicity, limited trafficking, and immunosuppressive TME, that limit their clinical efficacy [12], highlighting the need for a better understanding of MSLN functional roles in tumor progression and TME remodeling. The gene discussed is MSLN; the disease is neoplasm.